Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
about
Challenges of Using High-Dose Fractionation Radiotherapy in Combination TherapyFibroblasts, an inconspicuous but essential player in colon cancer development and progressionRemodeling Components of the Tumor Microenvironment to Enhance Cancer TherapyInhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical DataOverview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial FluidVascular normalization and cancer immunotherapyImmunotherapy advances for glioblastomaRadiation meets immunotherapy - a perfect match in the era of combination therapy?Nanomedicine therapeutic approaches to overcome cancer drug resistanceTrial Watch:: Oncolytic viruses for cancer therapyMolecular pathways: not a simple tube--the many functions of blood vesselsAn Integrative Platform for Three-dimensional Quantitative Analysis of Spatially Heterogeneous Metastasis LandscapesT cell exclusion, immune privilege, and the tumor microenvironmentTheory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell KillIntravital Microscopy Imaging Approaches for Image-Guided Drug Delivery SystemsTargeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Development of a mathematical model to estimate intra-tumor oxygen concentrations through multi-parametric imaging.Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsFlattened microvessel independently predicts poor prognosis of patients with non-small cell lung cancer.Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.The role of mechanical forces in tumor growth and therapyGentian violet: a 19th century drug re-emerges in the 21st centuryImmune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Nivolumab in NSCLC: latest evidence and clinical potentialSystemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection.Bevacizumab plus ipilimumab in patients with metastatic melanoma.Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Vascular normalization induced by sinomenine hydrochloride results in suppressed mammary tumor growth and metastasisCXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in miceInvestigation on the role of VEGF gene polymorphisms in the risk of osteosarcomaAxitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA.Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future developmentImmunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice
P2860
Q26742107-891FA8E6-DBDF-4220-B0B0-2D88BAB64732Q26747341-194BAE90-0004-4742-BAA4-E0B60FE83869Q26777144-A2D64686-BCF2-4F17-AA25-84E9E74B8156Q26781098-4622BB56-26B0-4167-AD0A-F17A6C1E16A4Q26799981-3A1E4A42-09DF-499D-9C2A-76DFE91CFBD8Q26827437-C31FEBFB-6C0D-4F4E-88D1-CE7437B89D14Q26866513-624C18C7-E8DF-4F67-A5F0-42E8338FAEDEQ27005913-0DFE1ED4-10ED-44C3-BD36-1B88DD6D7A66Q27011692-9A9B7C7F-5374-4B1F-9394-A7FA056D6DF0Q27021951-5CC6EE00-1742-4DA3-915B-64EE2AA348DFQ27025036-799ADD7B-ABE6-4744-A861-E94FA7756C6DQ27322772-B35B9E2F-32D0-4388-94E4-A60D98DD4759Q28259872-44EFAE25-30C8-4D4D-8ADD-C027E571C3A5Q28550211-11CA3CED-4EBF-45DC-9A88-34537EE6D86AQ28553638-F5AC76DC-AE96-4028-81AD-1FE87A02E8B7Q29248893-CB68B76D-52CB-4C86-BE4D-D1F22AB7BBEBQ30399006-9ACE336E-75A6-4D3F-A532-6CA2AD12833BQ30821877-4A6B72BF-B60A-449C-8674-6C8D0300358DQ33576750-3597082F-33E6-4793-8BD8-9EB5749E4AE0Q33728242-E2DE427D-0A1F-4A95-830C-86BBFFF9F322Q33920350-8F531F11-83BD-4FE6-9CA6-AA0F192026C0Q33942378-FA4E9E5F-23E7-43E6-B02C-E3CE810FC0C3Q34377198-80EB2072-3B48-4E37-A669-ABF815B4BCF0Q34458617-49E85387-1EFD-482F-9895-851CB13EBD71Q34466452-6433B11B-ABBE-4634-B789-5208707911CAQ34587649-EC44F81C-3BCD-4192-B0EA-EC188627F391Q35012765-57A0FC58-4CE3-47A6-AB64-52B8A9217DA8Q35067209-6F21E990-BEEC-4D8D-8925-7270B4DA8177Q35078406-6AFB78D0-FC88-40A4-81BC-9BCF8BA97517Q35090116-CF1A769C-EF0C-40FC-9E97-4E6681608D22Q35104052-732C71C4-DC34-4632-B7B3-73FBBBDBB17DQ35157184-599E2BCD-B9EA-461E-9268-F9761E8AB2B8Q35528287-A33594A3-5F98-43FD-AE8F-FA4060FBCCA9Q35765926-1914114F-8CD4-4B2A-8104-248D32A0B839Q35798966-673514C8-04EE-4497-BEAE-AF3793FA34E4Q35895174-25B778D5-B304-407E-91BC-C6182372301DQ36029752-DEDD0925-3B26-4F40-B55F-FFD6C800FBADQ36107937-65842BF5-8D8B-4ECA-8B3B-FCCBF9493F6EQ36224057-8F404BFF-E588-4515-AFE2-845E1BDD0A29Q36249314-1203940A-01C7-4883-95F4-54F1CC5BFA42
P2860
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
@en
type
label
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
@en
prefLabel
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
@en
P2093
P2860
P1433
P1476
Vascular normalization as an emerging strategy to enhance cancer immunotherapy.
@en
P2093
Dai Fukumura
Dan G Duda
Rakesh K Jain
Yuhui Huang
P2860
P304
P356
10.1158/0008-5472.CAN-12-4354
P407
P577
2013-02-25T00:00:00Z